RWD86 Characteristics of Patients with Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Who Received Pembrolizumab as Part of an Early Access Program in Accordance with KN-355 Labelling
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.2803
https://www.valueinhealthjournal.com/article/S1098-3015(23)05933-8/fulltext
Section Title :
Section Order :
12139
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)05933-8&doi=10.1016/j.jval.2023.09.2803